Similarly, breast cancer patients in stages I-II account for 80% of the total participants in the study of Keyomarsi et al. Based on the above, we speculate that the prognostic roles of cyclin D3 might be different in diverse cancer stage. This evidence concerns the gene CCND3 and breast carcinoma.